FDA Approves Updated Safety Labeling for Strattera

The FDA has approved updated safety labeling for Strattera® to include information regarding use of Strattera in patients with ADHD who have a comorbid tic disorder.

Wednesday October 17th - 11:35am

The U.S. Food and Drug Administration (FDA) has approved updated safety labeling for Strattera (atomexetine HCI), the non-stimulant attention deficit disorder (ADD ADHD) medication, to indicate that it does not worsen tics in patients with both ADHD and a tic disorder such as Tourette’s syndrome.

The label update was based on a placebo-controlled study of 148 pediatric patients with ADHD and a tic disorder.

For more information see Strattera.com or Download the PDF

Copyright © 1998 - 2013 New Hope Media LLC. All rights reserved. Your use of this site is governed by our Terms of Service and Privacy Policy.
ADDitude does not provide medical advice, diagnosis, or treatment. The material on this web site is provided for educational purposes only. See additional information.
New Hope Media, 39 W. 37th Street, 15th Floor, New York, NY 10018